

PATENT  
0508-1011-1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: BARTHOLEYNS et al.  
Appl. No.: New Group: Unknown  
Filed: July 21, 2003 Examiner: Unknown  
For: COMBINED PREPARATION FOR THE TREATMENT  
OF NEOPLASIC DISEASES OR OF INFECTIOUS  
DISEASES

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION WITH CONTINUATION-IN-PART OR  
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Date: July 21, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).

09/647,529

U.S. Filing Date(s)

November 29, 2000

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.


If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 25-0120.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

YOUNG & THOMPSON

By

  
Robert J. Patch, #17,355

RJP/psf

745 South 23<sup>rd</sup> Street  
Arlington, Virginia 22202  
(703) 521-2297

Enclosures: ☒ PTO-1449  
☐ References  
☐ Foreign Search Report  
☐ Other:

(Rev. 04/19/2000)

(Use several sheets if necessary)

0508-1011-1

NEW

**BARTHOLEYS et al.**

**July 21, 2003**

Group Art Unit:

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

		by B. Hennemann et al., "Monocyte/Macrophage Activation by Immunostimulators: Role in Cancer Therapy", <u>CLINICAL IMMUNOTHERAPEUTICS</u> , 1996, pages 294-308.
		by B. Hennemann et al., "Adoptive Immunotherapy with Tumor-Cytotoxic Macrophages Derived from Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhuGM-CSF) Mobilized Peripheral Blood Monocytes", <u>JOURNAL OF IMMUNOTHERAPY</u> , 1997, pages 365-361.
		by J. BARTOLEYNS et al., "Immune Therapy with Macrophages: Present Status and Critical Requirements for Implementation", <u>IMMUNOBIOLOGY</u> , 1996, pages 550-562.
		by T. Takeda et al., "The effect of local immunotherapy for breast cancer using a mixture of OK-432 and fibrinogen supplemented with activated macrophages", <u>BIOOTHERAPY</u> , 1994, pages 47-54.
		Fidler and Kleinerman, <u>J. Clin. Oncol.</u> , 1984, 2:937-943
		Silagi, et al., <u>Int J Cancer</u> , 1988, 41:315-322
		Schachter, et al., 1998, <u>Cancer biotherapy and Radiopharmaceuticals</u> 13: 155-164
		Williams, et al., 1997, <u>Br J Haematol</u> , 98(4):960-8

EXAMINER:

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

\* Abstract provided for the Examiner's convenience